# GLP-1 treatment, creatinine and eGFR: reading the change

Kidney results during weight loss need context. Dehydration can matter, while creatinine-based estimates are also influenced by muscle and diet.

Canonical: https://velri.co/blog/glp1-creatinine-egfr-kidney-markers-rapid-weight-loss
Publisher: Velri (https://velri.co/about)
Published: 2026-07-03
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

A change in creatinine or estimated GFR during weight loss can have more than one explanation. Kidney filtration matters, but creatinine is also affected by muscle size and diet. Meanwhile, vomiting or diarrhea during GLP-1 treatment can cause dehydration and sometimes acute kidney injury. [1][2][3]

## What does eGFR estimate?

Estimated glomerular filtration rate, or eGFR, is a calculation used to assess how well the kidneys filter. It commonly uses blood creatinine, a waste product related to muscle breakdown and dietary protein. [1]

Because muscle mass, diet and some illnesses can affect creatinine, the estimate has limits. A change in body composition during weight loss can make those limits relevant when comparing results. [1]

For example, a lower creatinine value should be considered alongside changes in muscle and nutrition before all of the apparent eGFR improvement is attributed to better filtration. [1]

## Why dehydration changes the priority

The semaglutide and tirzepatide weight-management labels warn about acute kidney injury associated with fluid depletion. Many reported cases occurred after gastrointestinal symptoms such as vomiting or diarrhea. The labels call for kidney-function monitoring when adverse reactions could cause fluid loss, especially during initiation or escalation. [2][3]

That is a different issue from gradual changes in creatinine production. A result obtained while someone is repeatedly vomiting should be interpreted with that illness history. [2][3]

## What information helps clarify a result?

The previous kidney results, the timing of the blood draw, recent digestive symptoms and changes in food intake or body composition all provide context. The National Kidney Foundation also describes estimates using cystatin C, another blood marker, when assessing filtration. [1]

The need for another test or a repeat measurement depends on the clinical question. The result should be interpreted alongside symptoms and earlier kidney measurements. [1]

Markedly reduced urination, confusion or fainting can accompany severe dehydration and need immediate medical help. Those symptoms should not wait for the next scheduled weight-management visit. [4]

## Sources
[1] Estimated GFR (eGFR) Test: Kidney Function Levels, Stages, and What to Do Next | National Kidney Foundation (2026). https://www.kidney.org/kidney-topics/estimated-glomerular-filtration-rate-egfr
[2] DailyMed - WEGOVY- semaglutide injection, solution
WEGOVY- semaglutide tablet (2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
[3] DailyMed - ZEPBOUND- tirzepatide injection, solution
ZEPBOUND- tirzepatide injection, solution
ZEPBOUND KWIKPEN- tirzepatide injection, solution (2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
[4] Dehydration: MedlinePlus (2024). https://medlineplus.gov/dehydration.html

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support